Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu
Managing Director & CEO, Silviu Itescu
Source: Mesoblast
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthcare stock Mesoblast (MSB) is planning to meet with the US Food and Drug Administration (FDA) for its chronic low back pain program
  • Recently, the company completed a trial on 404 patients with inflammatory back pain using its stem cell drug Rexlemestrocel-L
  • Now, Mesoblast wants to bring these results to the FDA in the current quarter to discuss the pathway to US regulatory approval
  • On the market this morning, Mesoblast is up 4.55 per cent and is trading at $2.07 per share

Mesoblast (MSB) is planning to meet with the US Food and Drug Administration (FDA) for its chronic low back pain program.

The company recently completed a 404-patient trial using its stem cell drug Rexlemestrocel-L.

The trial tested the drug on patients with chronic inflammatory back pain due to degenerative disc disease.

Now, Mesoblast wants to bring these results to the FDA in the current quarter to discuss the pathway to US regulatory approval.

“We look forward to discussing with the FDA the most efficient path forward given the durable pain reduction for at least two years and the opioid-sparing activity from a single administration of rexlemestrocel-L that was observed in the recent phase three trial,” Chief Medical Officer Dr Fred Grossman said.

Notably, chronic low back pain affects approximately 10-15 per cent of the adult population, equivalent to more than 30 million people in the United States.

Mesoblast will use the results from a planned US trial to support potential product approvals in both the US and EU.

In line with this strategy, Mesoblast and its partner in Europe and Latin America, Grünenthal, have changed their collaboration agreement, leaving Mesoblast with US$112.5 million (around A$150 million) of funding money.

On the market this morning, Mesoblast is up 4.55 per cent and is trading at $2.07 per share at 10:09 am AEST.

MSB by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…